Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, produces superior glycemic control and greater weight loss compared to GLP-1 receptor agonists (semaglutide, dulaglutide) and insulin analogs (degludec, glargine) in patients with type 2 diabetes.
If you have Type 2 Diabetes or obesity, Tirzepatide is a once-weekly injection that lowers blood sugar and reduces body weight more effectively than current GLP-1 drugs (like semaglutide) or insulin. It works by mimicking two gut hormones (GIP and GLP-1). Common side effects are gastrointestinal, but they often decrease over time. Consult a doctor to see if you are a candidate.
when compared to the GLP-1RAs, the SURPASS-2 trial results showed that tirzepatide reduced glycated hemoglobin and fasting serum glucose levels more than semaglutide at all dosages (5, 10, and 15 mg)... Overall, tirzepatide outperforms GLP-1RAs and insulin in terms of blood glucose management
Why this rating
Based on Phase III SURPASS trials (SURPASS-2, 3, 4) comparing against active comparators, though the paper is a review summarizing these trials.
Source
Research Progress on the GIP/GLP-1 Receptor Coagonist Tirzepatide, a Rising Star in Type 2 Diabetes
Zijun Ma et al. · Journal of Diabetes Research · 2023
DOI 10.1155/2023/5891532
More from this paper
- Tirzepatide demonstrates potential for cardiovascular protection, including reduced risk of major adverse cardiovascular events (MACE-4) and improved lipid profiles, in patients with Type 2 Diabetes.Moderate
- Tirzepatide shows promise for treating Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) by reducing liver fat content and improving liver enzymes, likely through indirect weight loss and metabolic effects.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →